Therapeutic Potential of

Background: Glioblastoma (GB) is a highly aggressive and invasive brain tumor characterized by a poor prognosis. The Danshen ( Materials and Methods: Cell viability and migration were assessed using 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide and wound healing assays, respectively. The cell cycle and apoptosis were evaluated using flow cytometry. The in vivo effect of DCE was determined using a U87-MG GB xenograft model in BALB/c-nude mice. The gene expression profile of DCE-treated tumor tissue was assessed using RNA sequencing, with validation of key genes by using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Results: DCE treatment significantly reduced cell viability in both the U87-MG and DBTRG-05MG GB cell lines. Additionally, DCE notably induced G0/G1 cell cycle arrest and promoted apoptosis in both cell lines. Furthermore, DCE effectively inhibited cell migration in both GB cell lines. The in vivo results revealed that DCE significantly suppressed tumor growth in the GB xenograft mouse model. qRT-PCR analysis indicated that the anticancer activity of DCE is associated with the downregulation of Conclusion: DCE effectively suppressed the progression of GB in both in vitro and in vivo models, likely through modulation of modulating pro-inflammatory signaling pathways. These findings highlight DCE as a promising candidate for therapeutic development against GB.